Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss

NCT ID: NCT06149221

Last Updated: 2024-04-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-01

Study Completion Date

2024-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NTAP treatment

Treatment arm subjects receive the trial intervention

Group Type EXPERIMENTAL

NTAP

Intervention Type DEVICE

Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NTAP

Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of mild-to moderate androgenetic alopecia
* ability to keep in-person follow-up appointments

Exclusion Criteria

* any inflammatory scalp condition
* starting or discontinuing any hair loss treatments within 6 months of start date
* allergy to any components of the carrier solution
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Peter C. Friedman

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Peter C. Friedman

President

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Skin Center Dermatology Group

New City, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DCAP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fractional Photothermolysis for Hair Follicle Induction
NCT03382184 ACTIVE_NOT_RECRUITING EARLY_PHASE1
The Utility of Platelet Rich Plasma in Hair Loss
NCT03376581 COMPLETED EARLY_PHASE1
Hydraderm for Androgenic Alopecia
NCT05426629 WITHDRAWN PHASE4